Please login to the form below

Not currently logged in
Email:
Password:

arthritis

This page shows the latest arthritis news and features for those working in and with pharma, biotech and healthcare.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner

that resulted in commercial products including cholesterol therapy Praluent (alirocumab), Dupixent (dupilumab) for atopic dermatitis and rheumatoid arthritis therapy Kevzara (sarilumab).

Latest news

  • Gilead and Galapagos close in on filing for Xeljanz rival Gilead and Galapagos close in on filing for Xeljanz rival

    Belgian biotech gearing up for first approval. Galapagos and Gilead Sciences have a pair of positive phase 3 trials for their JAK inhibitor filgotinib in rheumatoid arthritis that they say make ... RA and the rest from other diseases such as psoriatic

  • AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

    Risankizumab is also being in clinical trials for a number of other inflammatory diseases, including Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. ... AbbVie has another inflammation treatment nearing the market,

  • EMA could follow FDA’s Xeljanz blood clot warning EMA could follow FDA’s Xeljanz blood clot warning

    Xeljanz is currently approved in both the US and EU for patients with rheumatoid arthritis (RA) and psoriatic arthritis, but at an authorised dose of 5mg, twice daily. ... In the EU and the US, this dose is higher than the authorised dose of 5 mg twice

  • Sanofi extends growth spurt thanks to Genzyme, Dupixent Sanofi extends growth spurt thanks to Genzyme, Dupixent

    Other new products in Sanofi’s portfolio are still not looking too buoyant, particularly Kevzara (sarilumab) for rheumatoid arthritis and high cholesterol therapy Praluent (alirocumab), both of which have struggled to

  • Gilead awaits CEO and readouts to revive fortunes Gilead awaits CEO and readouts to revive fortunes

    and the fatty liver disease non-alcoholic steatohepatitis (NASH) and selective JAK1 inhibitor f ilgotinib in rheumatoid arthritis. ... Also of great importance are two phase 3 studies, FINCH 1 and FINCH 3 of filgotinib in rheumatoid arthritis.

More from news
Approximately 93 fully matching, plus 582 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that

  • NHS regional footprints NHS regional footprints

    For example, the CCG has contracted services for musculoskeletal disorders (MSK), from the Nottinghamshire Integrated Care Partnership (ICP), which is now delivering services around rheumatology, arthritis, physiotherapy, imaging, primary care

  • Nudge-nudge, think-think Nudge-nudge, think-think

    Entertainment is a great way of stimulating behaviour change.”. A good example of this is the OuchieBand campaign for Junior Idiopathic Arthritis (JIA), where we combined convenience with entertainment.

  • Insights from Cannes Lions Health Festival 2018 Insights from Cannes Lions Health Festival 2018

    When we think of arthritis we think of the old and frail. ... But Systemic Juvenile Idiopathic Arthritis (sJIA) actually affects a significant number of children.

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

More from intelligence
Approximately 0 fully matching, plus 46 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 9 fully matching, plus 30 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics